In collaboration with Finish KAMU Health and Swiss CSS insurance, ETH spinoff Resmonics has launched its first product ResGuard Med. The CE-certified solution gives patients with chronic and acute respiratory symptoms unique insights into their disease.
Digital health startup Resmonics developed ResGuard Med, a CE-certified software as a medical device that uses artificial intelligence to help users decide whether their respiratory symptoms warrant medical attention by automatically detecting and scoring a user’s cough at night using only the smartphone’s built-in microphone. Patients only need to place their smartphones in their bedrooms at night to get an objective assessment of symptom severity and disease progression.
In collaboration with its first two pilot customers, Resmonics launched two products at the end of December 2021: a software development kit, which allows companies to integrate ResGuard Med’s features into their already available smartphone apps, and a stand-alone white-label app. Resmonics’ CEO Peter Tinschert remarks: “It was a very gratifying end of the year for us: After five years of research, development, and regulatory approval, ResGuard Med made it from bench to bedside”.
With KAMU Health, Finnish patients with asthma and Chronic obstructive pulmonary disease (COPD) can get unique insights into their cough by using the KAMU Health app. “Nocturnal coughing is a central symptom in chronic lung conditions, but hard to measure objectively. For the first time, Resmonics makes it possible to monitor the coughing in a reliable and cost-efficient way – and most importantly it is easy and effortless for the patient,” says Prof. Yrjö Salorinne, Chair of the Board at KAMU Health. “So far our collaboration and integration of technologies with Resmonics has been seamless.”
In Switzerland, the startup is working with its pre-seed investorr CSS Insurance to bring the myCough app to market. The myCough app is available for free for the next six months on Android and iOS in Switzerland, Germany, and Austria.
Michael Rieger, Head of Strategy and Corporate Services at CSS explains: “The myCough app is a unique and novel service that is well-aligned with our ambition to support innovative healthcare solutions with direct added value for our customers. We are very pleased to see how the Resmonics team has progressed within such a short time to deliver a market-ready product.”
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines